Financial year ending in --Mar '18 Mar '17 Mar '16 Mar '15

Amgens
Net Sales 157731 152565 153244 146608
Operaing Income/PBIDT 71841 69811 68558 59290
Caital Employed 370496 496538 464954 440363
Total R&D expenditure 26159 24934 26880 28490

Biocon
Net Sales 2419.2 2587.9 2301.8 2241.6
Operaing Income/PBIDT 442.9 690.6 701 557.2
Caital Employed 1976.3 1897.3 1600.8 1684.4
Reveue earnings in forex 470.9 509 343.2 1099.3
Revenue expenses in forex 734.8 789.9 818.2 105.7
Total R&D expenditure 1547 920 902 595

Criteria of Competitivenes
Net Sales
Amgen 157731 152565 153244 146608
Biocon 2419.2 2587.9 2301.8 2241.6
Difference in Sales 155311.8 149977.1 150942.2 144366.4

Total R&D expenditure

Amgen 26159 24934 26880 28490
Biocon 1547 920 902 595

Total R&D expenditure as % o

Amgen 16.6 16.3 17.5 19.4
Biocon 63.9 35.6 39.2 26.5
 Mar '14 Mar '13 Mar '12 Mar '11 Mar '10 Jump %Jump

Amgens
135289 127344 116473 107065 102620 55111 53.7
43337 41069 39039 30184 38815 33026 85.1
434007 407246 322749 303919 286986 83510 29.1
30079 28581 23660 22169 20258 5901 29.1

Biocon
2202.5 1938 1555.8 1561.1 1128.45 1290.75 114.4
533.9 443.3 400.1 608.4 357.95 84.95 23.7
1668.6 1494.7 1155.7 952.7 770.5 1205.8 156.5
1080.3 990.5 677.3 693.5 505.71 -34.81 -6.9
82.3 54.2 77.6 33.7 38 696.8 1833.7
190 411 292 449 595 952 160.0

ria of Competitiveness

135289 127344 116473 107065 102620

2202.5 1938 1555.8 1561.1 1128.45
133086.5 125406 114917.2 105503.9 101491.55

tal R&D expenditure

30079 28581 23660 22169 20258
190 411 292 449 595

D expenditure as % of sales
22.2 22.4 20.3 20.7 19.7
8.6 21.2 18.8 28.8 52.7